TICKERNERD
Menu
TDOCTDOCHealthcare · Health Information Services

TDOC Stock Forecast: Teladoc Health, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$6.28
−2.94% on the day

The 24 Wall Street analysts covering Teladoc Health, Inc. hold a median 12-month price target of $7.5 — +19.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 3 Sept 2026 — in the upper half.

Market cap
$1.2B
Ticker Nerd rank
67 / 100
Median analyst target
$7.50
Analysts covering
24
Revenue$606.9M−4.0% y/y
Operating income−$34.5M
Net income−$38.9M
Free cash flow$23.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.4%
1M
−6.4%
YTD
−10.3%
1Y
−17.7%
From 52W high
−35.4%
From 52W low
+40.5%
$4.47
$9.72
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TDOC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Teladoc Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Sept 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
96
Quality
79
Value
78
Growth
61
Revisions
45
Size
44
Issuance
43
Momentum
42
Volatility
25

Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (25): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TDOC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TDOC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$5.00$6.00$7.00$8.00$9.00$10.00$11.00Oct 25Jan 26Apr 26Jul 26TDOCHigh $10.50Median $7.50Low $5.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says24 analysts
6 Buy18 Hold0 Sell
Low $5.50Median $7.50High $10.50

The green dot is the last close — the median target sits +19.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
3 Aug 2026CitigroupMaintainsNeutral$11 → $7.50
30 July 2026Canaccord GenuityMaintainsBuy$11 → $10
30 July 2026Evercore ISI GroupMaintainsIn-Line$10 → $7.50
21 July 2026Canaccord GenuityMaintainsBuy$10 → $11
21 July 2026Canaccord GenuityMaintainsBuy—
7 July 2026B of A SecuritiesMaintainsBuy$9.00 → $11
7 July 2026B of A SecuritiesMaintainsBuy—
5 May 2026CitigroupMaintainsNeutral—
8 Apr 2026Evercore ISI GroupMaintainsIn-Line—
26 Mar 2026BarclaysMaintainsEqual-Weight—
13 Mar 2026JP MorganMaintainsNeutral—
10 Mar 2026Deutsche BankUpgradeBuy—
3 Mar 2026CitigroupMaintainsNeutral—
3 Mar 2026OppenheimerMaintainsOutperform—
26 Feb 2026BMO CapitalMaintainsMarket Perform—
26 Feb 2026Canaccord GenuityMaintainsBuy—
26 Feb 2026Evercore ISI GroupMaintainsIn-Line—
26 Feb 2026Leerink PartnersMaintainsMarket Perform—
26 Feb 2026Piper SandlerReiteratesOverweight—
26 Feb 2026StifelMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TDOC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TDOC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Teladoc Health, Inc. returned −17.7% against +20.0% for the S&P 500, dividends included.

TDOC vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26TDOCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TDOC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Teladoc Health, Inc. (TDOC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.7×

Cheaper than 90% of US stocks

Price / sales
0.5×

Cheaper than 83% of US stocks

Price / book
0.9×

Cheaper than 77% of US stocks

EV / EBITDA
21.7×

Cheaper than 14% of US stocks

Growth & margins
Revenue growth (YoY)
−4.0%

Higher than 21% of US stocks

Earnings growth (YoY)
−4.0%

Higher than 31% of US stocks

Gross margin
68.6%

Higher than 82% of US stocks

Operating margin
−5.7%

Higher than 27% of US stocks

Net margin
−7.1%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−13.0%

Higher than 34% of US stocks

Return on assets
−3.2%

Higher than 34% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Teladoc Health, Inc. (TDOC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Teladoc Health, Inc. has a market value of $1.2B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $2.5B. The latest quarter shrank 4.0% year on year.

  • Net income over the same four quarters: −$177.4M, a −7.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−11.43.

  • Free cash flow in the twelve months to 30 June 2026: $118.1M, after $130.4M of capital spending.

  • Shares outstanding: 181.6M.

  • Trailing P/E: −5.7×; forward P/E: −8.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Teladoc Health, Inc. employs 4,648 people — $536K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Sept 2026

Data provided by Twelve Data

Peers

TDOC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
TDOCTeladoc Health, Inc.$1.2B
67
GDRXGoodRx Holdings, Inc.$1.2B
75
CERTCertara, Inc.$1.3B
56
OMDAOmada Health, Inc.$1.3B
82
HSTMHealthStream, Inc.$882.3M
94
TALKTalkspace, Inc.$879.4M
—
SDGRSchrödinger, Inc.$1.5B
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Teladoc Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TDOC news & analysis

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

GlobeNewsWire · 3 Sept 2026neutral

Teladoc Health announced that it issued employee inducement awards to a new employee under NYSE Rule 303A.08, a standard corporate practice for attracting new hires. The announcement was made on September 3, 2026 via GlobeNewsWire.

Why it matters — TDOC watchers would care because the issuance of inducement stock awards is a routine part of the company's executive compensation and hiring practices, and such grants can affect share dilution over time.

Here's Why Investors Should Stay Neutral on TDOC Stock for Now

Zacks Investment Research · 2 Sept 2026neutral

Zacks Investment Research advises investors to remain neutral on Teladoc Health (TDOC) stock for now. The note cites growth support from chronic care, international expansion, and Teladoc One, while acknowledging that BetterHelp weakness and company losses temper the overall outlook.

Why it matters — TDOC watchers would care because the item balances Teladoc's growth drivers with its ongoing BetterHelp weakness and losses, informing how they assess the company's current position.

Teladoc appoints insurance executive Michael Grasher as CFO

Reuters · 31 Aug 2026positive

Teladoc Health announced the appointment of Michael Grasher as its chief financial officer on Monday. Grasher, an industry veteran with insurance-sector experience, joins to help the company manage growing demand for its insurance-covered business.

Why it matters — A seasoned insurance executive at the CFO post could strengthen Teladoc's financial leadership as it focuses on its expanding insurance-reimbursed operations.

Teladoc Health Appoints Michael Grasher as Chief Financial Officer

GlobeNewsWire · 31 Aug 2026positive

Teladoc Health announced the appointment of Michael Grasher as Chief Financial Officer, effective immediately. Grasher brings over three decades of experience in insurance and financial services, including more than 12 years in CFO roles at public and private companies.

Why it matters — A seasoned CFO with deep financial services experience joins Teladoc as it advances its strategy aimed at delivering disciplined, sustainable growth, which is relevant to those following the company's financial leadership.

Teladoc (TDOC) Down 3.3% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research · 28 Aug 2026negative

Teladoc reported earnings 30 days ago, and its stock is down 3.3% since that report. The article raises the question of whether the stock can rebound following this decline.

Why it matters — TDOC watchers would care because the post-earnings decline reflects recent market reaction to the company's latest results and raises questions about its near-term share price direction.

FAQ

Frequently asked questions about TDOC stock

What is the TDOC stock price forecast for 2026-2027?

The 24 Wall Street analysts covering Teladoc Health, Inc. have a median 12-month price target of $7.5, with estimates ranging from $5.5 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TDOC stock a buy right now?

Of the 24 analysts covering Teladoc Health, Inc., 6 rate it a Buy, 18 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Teladoc Health, Inc. 67 out of 100 across roughly 4,600 US stocks as at 3 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TDOC?

As at 3 Sept 2026, Teladoc Health, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).

Will TDOC stock go up?

No one can know that. What the data says: the median 12-month target from 24 analysts implies +19.4% from the last close, and Ticker Nerd's factor model ranks Teladoc Health, Inc. 67 out of 100 as at 3 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TDOC stock forecast for 2030?

No analyst covering Teladoc Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TDOC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.5 to $11 over the next 12 months.

How has TDOC stock performed over the past year?

Teladoc Health, Inc. returned -17.7% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Teladoc Health, Inc. do?

Teladoc Health Inc. is a virtual healthcare company that provides technology-enabled medical services for patients, employers, health plans, hospitals, and health systems.

What is the latest news on TDOC?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08". Teladoc Health announced that it issued employee inducement awards to a new employee under NYSE Rule 303A.08, a standard corporate practice for attracting new hires. The announcement was made on September 3, 2026 via GlobeNewsWire.

Company

About Teladoc Health, Inc.

Teladoc Health Inc. is a virtual healthcare company that provides technology-enabled medical services for patients, employers, health plans, hospitals, and health systems. Its platform supports remote access to general medical care, mental health services, chronic condition management, specialty consultations, and expert medical opinions through phone, video, mobile, and web-based channels. The company operates through two main business segments: Integrated Care, which delivers enterprise virtual care solutions, and BetterHelp, a direct-to-consumer online mental health platform. Teladoc Health Inc. plays a significant role in the digital health market by connecting clinicians and care seekers through scalable, on-demand care delivery across a broad range of healthcare needs.

CEO Mr. Charles Divita III, CPA · 4,648 employees · United States · https://www.teladochealth.com